文献速递乳腺癌

乳腺癌指数在绝经前早期激素受体阳性乳腺癌患者中的研究

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
PubMed 文献 · JAMA Oncol · 2024-01-01

该前瞻性-回顾性转化研究利用SOFT试验中1687例绝经前激素受体阳性早期乳腺癌患者的肿瘤标本,评估乳腺癌指数(BCI)对卵巢功能抑制(OFS)获益的预测和预后价值。中位随访12年,BCI(H/I)低表达患者从依西美坦联合OFS和他莫昔芬联合OFS中获得BCFI绝对获益,而BCI(H/I)高表达患者未获益。BCI连续指数在N0亚组中对DRFI有显著预后价值。

要点

  • BCI(H/I)低表达患者从依西美坦联合OFS获得12年BCFI绝对获益11.6%(HR 0.48),从他莫昔芬联合OFS获得7.3%(HR 0.69)。
  • BCI(H/I)高表达患者从依西美坦联合OFS(绝对获益-0.4%,HR 1.03)或他莫昔芬联合OFS(绝对获益-1.2%,HR 1.05)均未获益。
  • BCI连续指数在N0亚组中对DRFI有显著预后价值(n=1110,P=0.004),低、中、高风险12年DRFI分别为95.9%、90.8%、86.3%。

核心结论

  • 在SOFT试验患者中,BCI被证实对绝经前激素受体阳性乳腺癌具有预后价值。
  • BCI(H/I)低表达肿瘤患者从含OFS的辅助内分泌治疗中获益大于BCI(H/I)高表达肿瘤患者。
  • BCI(H/I)低表达状态可能识别可能从更强化的内分泌治疗中获益的绝经前患者。

研究设计与样本

  • 前瞻性-回顾性转化研究,使用SOFT试验中1718例有肿瘤标本的患者,其中1687例(98.2%)标本产出足够RNA用于BCI检测。
  • 患者随机接受5年他莫昔芬单药、他莫昔芬联合OFS或依西美坦联合OFS。
  • BCI检测对临床数据和结局设盲,预设假设为BCI(H/I)高表达肿瘤从OFS获益更多且高BCI预示预后更差。
  • 数据收集于2003年12月至2021年4月,分析于2022年5月至2022年10月。

主要发现

  • 中位随访12年(IQR 10.5-13.4),512例(30.3%)患者年龄小于40岁。
  • BCI(H/I)低表达972例(57.6%),高表达715例(42.4%)。
  • BCI(H/I)低表达患者从依西美坦联合OFS获得12年BCFI绝对获益11.6%(HR 0.48,95%CI 0.33-0.71),从他莫昔芬联合OFS获得绝对获益7.3%(HR 0.69,95%CI 0.48-0.97),均相对于他莫昔芬单药。
  • BCI(H/I)高表达患者从依西美坦联合OFS未获益(绝对获益-0.4%,HR 1.03,95%CI 0.70-1.53;交互作用P=0.006),从他莫昔芬联合OFS未获益(绝对获益-1.2%,HR 1.05,95%CI 0.72-1.54;交互作用P=0.11),均相对于他莫昔芬单药。
  • BCI连续指数在N0亚组中对DRFI有显著预后价值(n=1110,P=0.004),BCI低危、中危、高危N0肿瘤的12年DRFI分别为95.9%、90.8%、86.3%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adjuvant ovarian function suppression (OFS) with oral endocrine therapy improves outcomes for premenopausal patients with hormone receptor-positive (HR+) breast cancer but adds adverse effects. A genomic biomarker for selecting patients most likely to benefit from OFS-based treatment is lacking. OBJECTIVE: To assess the predictive and prognostic performance of the Breast Cancer Index (BCI) for OFS benefit in premenopausal women with HR+ breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This prospective-retrospective translational study used all available tumor tissue samples from female patients from the Suppression of Ovarian Function Trial (SOFT). These individuals were randomized to receive 5 years of adjuvant tamoxifen alone, tamoxifen plus OFS, or exemestane plus OFS. BCI testing was performed blinded to clinical data and outcome. The a priori hypothesis was that BCI HOXB13/IL17BR ratio (BCI[H/I])-high tumors would benefit more from OFS and high BCI portended poorer prognosis in this population. Settings spanned multiple centers internationally. Participants included premenopausal female patients with HR+ early breast cancer with specimens in the International Breast Cancer Study Group tumor repository available for RNA extraction. Data were collected from December 2003 to April 2021 and were analyzed from May 2022 to October 2022. MAIN OUTCOMES AND MEASURES: Primary end points were breast cancer-free interval (BCFI) for the predictive analysis and distant recurrence-free interval (DRFI) for the prognostic analyses. RESULTS: Tumor specimens were available for 1718 of the 3047 female patients in the SOFT intention-to-treat population. The 1687 patients (98.2%) who had specimens that yielded sufficient RNA for BCI testing represented the parent trial population. The median (IQR) follow-up time was 12 (10.5-13.4) years, and 512 patients (30.3%) were younger than 40 years. Tumors were BCI(H/I)-low for 972 patients (57.6%) and BCI(H/I)-high for 715 patients (42.4%). Patients with tumors classified as BCI(H/I)-low exhibited a 12-year absolute benefit in BCFI of 11.6% from exemestane plus OFS (hazard ratio [HR], 0.48 [95% CI, 0.33-0.71]) and an absolute benefit of 7.3% from tamoxifen plus OFS (HR, 0.69 [95% CI, 0.48-0.97]) relative to tamoxifen alone. In contrast, patients with BCI(H/I)-high tumors did not benefit from either exemestane plus OFS (absolute benefit, -0.4%; HR, 1.03 [95% CI, 0.70-1.53]; P for interaction = .006) or tamoxifen plus OFS (absolute benefit, -1.2%; HR, 1.05 [95% CI, 0.72-1.54]; P for interaction = .11) compared with tamoxifen alone. BCI continuous index was significantly prognostic in the N0 subgroup for DRFI (n = 1110; P = .004), with 12-year DRFI of 95.9%, 90.8%, and 86.3% in BCI low-risk, intermediate-risk, and high-risk N0 cancers, respectively. CONCLUSIONS AND RELEVANCE: In this prospective-retrospective translational study of patients enrolled in SOFT, BCI was confirmed as prognostic in premenopausal women with HR+ breast cancer. The benefit from OFS-containing adjuvant endocrine therapy was greater for patients with BCI(H/I)-low tumors than BCI(H/I)-high tumors. BCI(H/I)-low status may identify premenopausal patients who are likely to benefit from this more intensive endocrine therapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. O'Regan RM, Zhang Y, Fleming GF, et al. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024. PMID: 39145953. doi:10.1001/jamaoncol.2024.3044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。